
Incyte Reports Positive Phase III Results for Tafasitamab in First-Line DLBCL Treatment
Incyte has announced encouraging top-line findings from its pivotal Phase III frontMIND trial, evaluating tafasitamab (marketed as Monjuvi/Minjuvi) in combination with lenalidomide and the standard





















